Developer docs
API playgroundTry for free, no card

Search company profiles

memodio

Full company profile

uuid0003scg

Namestring
memodio
Legal namestring
memodio GmbH
Websiteurl
memodio-app.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

memodio GmbH is a Potsdam-based digital health company that develops and operates a prescription digital therapeutic (DiGA) for the prevention and therapy of mild cognitive impairment (MCI) and mild dementia. The product is a Class I medical device (Medizinprodukt Klasse I) under the EU Medical Device Regulation, delivered as a mobile application on iOS and Android. It received DiGA approval from the German Federal Institute for Drugs and Medical Devices (BfArM) in January 2026 (PZN 20386496), making it fully reimbursable by all German statutory health insurers. The therapeutic approach is built on the FINGER multi-domain intervention model and combines six components: adaptive cognitive training, physical exercise, nutritional guidance, risk factor optimization (e.g., hypertension, dyslipidemia, hearing loss), social participation, and health literacy. Exercises auto-adjust in difficulty based on user performance, and a motivational system (virtual plant growing with completed exercises) supports adherence. Clinical validation was conducted via the MEMODIO_APP@CARE randomized controlled trial (n=140), which demonstrated statistically significant improvements in cognitive function (MoCA +9.3%, p<0.001), daily functioning (Amsterdam iADL +5.5%, p=0.002), physical activity (PAQ 50+ +21%, p=0.036), and quality of life (DemQOL +4.4%, p=0.025) over 12 weeks.

memodio is distributed exclusively through the regulated German prescription channel. Patients obtain the app via a physician's prescription (Kassenrezept or private prescription) for the indications MCI (F06.7), mild dementia (F00/F01), or Senilität (R54); memodio coordinates with health insurers to issue a 16-digit activation code. Therapy cycles are 12 weeks per prescription with follow-up prescriptions possible. Revenue flows from per-prescription-cycle reimbursements by statutory and private health insurers, with the company reporting 10,000+ users as of 2025. The company maintains ISO/IEC 27001:2022 certification, GDPR-compliant data processing, and uses the FHIR standard (MIO DiGA Toolkit v1.1.0) for data portability. A Scientific Advisory Board of leading German and European dementia researchers, including Prof. Mangialasche from the FINGER Network at Karolinska Institutet, provides clinical and scientific oversight. memodio is also developing a Spanish-market version (memodio vida). The company was founded in 2021 by Dr. Doron B. Stein, Dr. Felix Bicu, and Paul Zimmermann.

Short descriptiontext

memodio GmbH operates a German DiGA-approved prescription digital therapeutic (mobile app) that delivers personalized, multi-domain cognitive, physical, nutritional, and risk-factor therapy to patients with mild cognitive impairment and mild dementia, reimbursed by statutory health insurers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPotsdam, Germany
HQ citystring
Potsdam
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, dementia prevention, cognitive training software, digital health applications, medical device software
Industry2 codes
PRIMARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHSABAEAH
Cognitive Stimulation & Reminiscence Therapy (Non-Clinical)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care
NAICS code2 codes
  • Home Health Care Services62161
  • Services for the Elderly and Persons with Disabilities624120
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
  • Services-Home Health Care Services8082
Product category
Digital Therapeutics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1DiGA Prescription Reimbursement
TypeSubscription Recurring
Description

memodio is listed as a DiGA (Digitale Gesundheitsanwendung) in Germany. It is prescribed by physicians (GPs, specialists, psychotherapists) via statutory health insurance (GKV). All costs are covered 100% by statutory health insurers for patients — no co-payment required. Private health insurers also reimburse memodio. Revenue flows from insurer reimbursements to the company per prescription cycle.

memodio-app.com
2Seed Funding
TypeSubscription Recurring
Description

memodio raised €400,000 in a seed financing round in February 2023, co-financed by private investors via Companisto (crowdfunding platform). Additional public funding was received from EXIST, the German Federal Ministry for Economic Affairs and Climate Action, and the European Union / State of Brandenburg.

vc-magazin.de
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details1 tier
1Fully reimbursed DiGA — free at point of care for patients with statutory or private health insurance
ModelSubscriptionBilling cadenceMulti-year contract
Notes

The app is prescribed by a physician (Hausarzt, Facharzt, or Psychotherapeut) on a Kassenrezept or private prescription. memodio handles the paperwork with the patient's health insurer. The insurer sends the patient a 16-digit activation code by mail. The therapy duration is 12 weeks; a follow-up prescription is possible. No cost to the patient.

memodio-app.com
GTM typeB2C
B2C
Offering typeSoftware
Software
Core offering1 text field

memodio develops and operates a DiGA (Digitale Gesundheitsanwendung — Digital Health Application) mobile app that delivers a personalized, multi-domain therapy program for adults with mild cognitive impairment (MCI) and mild dementia. The app combines adaptive cognitive training, guided physical exercise, brain-healthy nutrition guidance, social participation content, risk factor optimization, and health literacy into a single auto-adaptive daily therapy unit of approximately 20 minutes. It is prescribed by physicians in Germany on a Kassenrezept or private prescription and is fully reimbursed by statutory and private health insurers (PZN 20386496).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 9.3% improvement in cognitive function (MoCA score) vs. control group after 12 weeks (p<0.001)
+6 more records
Product overview1 text field

memodio is a single, unified mobile application (DiGA — Digitale Gesundheitsanwendung) for dementia prevention and therapy. The core product is the memodio App, which integrates all non-pharmacological treatment components — cognitive brain training, physical exercise programs, dietary/nutrition guidance, risk factor optimization (e.g., blood pressure, hearing loss), social participation, and health literacy education — into one personalized, auto-adaptive daily therapy unit. The app is prescribed by physicians (PZN 20386496) and fully reimbursed by German statutory health insurers. A clinical study (MEMODIO_APP@CARE, n=140) demonstrated measurable improvements in cognitive function, daily living independence, physical activity, and quality of life after 12 weeks. memodio also provides a CME (continuing medical education) program for healthcare professionals.

Product and service1 record
1memodio App
CategoryDigital Therapeutics
Description

Mobile digital therapeutic (iOS 12+ and Android 6+) prescribed by physicians in Germany as a Class I medical device (DiGA, PZN 20386496) for adults with mild cognitive impairment (ICD-10 F06.7) or mild dementia (F00/F01). Delivers a personalized, auto-adaptive daily therapy unit of approximately 20 minutes combining cognitive training, physical exercise, brain-healthy nutrition guidance, social participation content, risk factor optimization (e.g., hypertension, dyslipidemia, hearing loss), and health literacy modules. Fully reimbursed by German statutory and private health insurers upon prescription, with therapy delivered as 12-week prescription cycles (follow-up prescriptions possible).

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

SpinLab, the HPI accelerator, is listed as a partner supporting memodio's development and growth.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Copenhagen Business School (CBS) in Denmark is listed as a clinical and scientific partner supporting memodio's research.

3Potsdam Transfer / University of Potsdam
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Potsdam Transfer and the University of Potsdam support memodio as an academic and technology transfer partner, including hosting the company at their facilities (c/o Potsdam Transfer).

memodio-app.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MTH Potsdam is listed as a clinical and scientific partner supporting memodio's development.

5FINGER Network (Karolinska Institutet)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The FINGER Network (FINGERS Brain健康) coordinated by the Karolinska Institutet in Stockholm is a core strategic partner. memodio's therapeutic approach is based on the FINGER model — a landmark multi-domain intervention trial demonstrating that combined physical, cognitive, nutritional, and vascular risk management can prevent cognitive decline. Prof. Mangialasche (FINGER Vice-President) serves on memodio's Scientific Advisory Board.

memodio-app.com
6memodio Scientific Advisory Board
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Scientific Advisory Board includes Prof. M.C. Polidori (University Hospital Cologne), Prof. E. Kalbe (University Hospital Cologne), Prof. S. Schneider (German Sport University Cologne), Prof. M. Heer (Bonn University of Applied Sciences), Prof. G. Nelles (Deutsche Gesellschaft für Neurologie), Dr. A. Quante (Gedächtnisklinik Berlin), Prof. Mangialasche (FINGER Network, Karolinska), and Prof. P. Mecocci (Italian Academy of Geriatrics). The board provides clinical and scientific oversight to ensure the app meets the highest medical standards.

memodio-app.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

memodio

Digital Therapeuticsmemodio-app.com

memodio GmbH operates a German DiGA-approved prescription digital therapeutic (mobile app) that delivers personalized, multi-domain cognitive, physical, nutritional, and risk-factor therapy to patients with mild cognitive impairment and mild dementia, reimbursed by statutory health insurers.

What memodio does

memodio GmbH is a Potsdam-based digital health company that develops and operates a prescription digital therapeutic (DiGA) for the prevention and therapy of mild cognitive impairment (MCI) and mild dementia. The product is a Class I medical device (Medizinprodukt Klasse I) under the EU Medical Device Regulation, delivered as a mobile application on iOS and Android. It received DiGA approval from the German Federal Institute for Drugs and Medical Devices (BfArM) in January 2026 (PZN 20386496), making it fully reimbursable by all German statutory health insurers. The therapeutic approach is built on the FINGER multi-domain intervention model and combines six components: adaptive cognitive training, physical exercise, nutritional guidance, risk factor optimization (e.g., hypertension, dyslipidemia, hearing loss), social participation, and health literacy. Exercises auto-adjust in difficulty based on user performance, and a motivational system (virtual plant growing with completed exercises) supports adherence. Clinical validation was conducted via the MEMODIO_APP@CARE randomized controlled trial (n=140), which demonstrated statistically significant improvements in cognitive function (MoCA +9.3%, p<0.001), daily functioning (Amsterdam iADL +5.5%, p=0.002), physical activity (PAQ 50+ +21%, p=0.036), and quality of life (DemQOL +4.4%, p=0.025) over 12 weeks.

memodio is distributed exclusively through the regulated German prescription channel. Patients obtain the app via a physician's prescription (Kassenrezept or private prescription) for the indications MCI (F06.7), mild dementia (F00/F01), or Senilität (R54); memodio coordinates with health insurers to issue a 16-digit activation code. Therapy cycles are 12 weeks per prescription with follow-up prescriptions possible. Revenue flows from per-prescription-cycle reimbursements by statutory and private health insurers, with the company reporting 10,000+ users as of 2025. The company maintains ISO/IEC 27001:2022 certification, GDPR-compliant data processing, and uses the FHIR standard (MIO DiGA Toolkit v1.1.0) for data portability. A Scientific Advisory Board of leading German and European dementia researchers, including Prof. Mangialasche from the FINGER Network at Karolinska Institutet, provides clinical and scientific oversight. memodio is also developing a Spanish-market version (memodio vida). The company was founded in 2021 by Dr. Doron B. Stein, Dr. Felix Bicu, and Paul Zimmermann.

memodio firmographics

Firmographics
Name
memodio
Legal name
memodio GmbH
Website
https://memodio-app.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
memodio GmbH operates a German DiGA-approved prescription digital therapeutic (mobile app) that delivers personalized, multi-domain cognitive, physical, nutritional, and risk-factor therapy to patients with mild cognitive impairment and mild dementia, reimbursed by statutory health insurers.
Ownership category
akta.pro rank

memodio industry classification

Industry
Product category
Digital Therapeutics
NAICS
Home Health Care Services (62161), Services for the Elderly and Persons with Disabilities (624120)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000), Services-Home Health Care Services (8082)
akta.pro industry
PRIMARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHSABAEAH
Cognitive Stimulation & Reminiscence Therapy (Non-Clinical)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care

Keywords

  • Digital therapeutics
  • Dementia prevention
  • Cognitive training software
  • Digital health applications
  • Medical device software

Where memodio is headquartered

Location

Headquarters

HQ city
Potsdam
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

memodio business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. DiGA Prescription Reimbursement: memodio is listed as a DiGA (Digitale Gesundheitsanwendung) in Germany. It is prescribed by physicians (GPs, specialists, psychotherapists) via statutory health insurance (GKV). All costs are covered 100% by statutory health insurers for patients — no co-payment required. Private health insurers also reimburse memodio. Revenue flows from insurer reimbursements to the company per prescription cycle.
  2. Seed Funding: memodio raised €400,000 in a seed financing round in February 2023, co-financed by private investors via Companisto (crowdfunding platform). Additional public funding was received from EXIST, the German Federal Ministry for Economic Affairs and Climate Action, and the European Union / State of Brandenburg.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractFully reimbursed DiGA — free at point of care for patients with statutory or private health insurance

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

memodio product offering

Product offering

Core offering

memodio develops and operates a DiGA (Digitale Gesundheitsanwendung — Digital Health Application) mobile app that delivers a personalized, multi-domain therapy program for adults with mild cognitive impairment (MCI) and mild dementia. The app combines adaptive cognitive training, guided physical exercise, brain-healthy nutrition guidance, social participation content, risk factor optimization, and health literacy into a single auto-adaptive daily therapy unit of approximately 20 minutes. It is prescribed by physicians in Germany on a Kassenrezept or private prescription and is fully reimbursed by statutory and private health insurers (PZN 20386496).

Product overview

memodio is a single, unified mobile application (DiGA — Digitale Gesundheitsanwendung) for dementia prevention and therapy. The core product is the memodio App, which integrates all non-pharmacological treatment components — cognitive brain training, physical exercise programs, dietary/nutrition guidance, risk factor optimization (e.g., blood pressure, hearing loss), social participation, and health literacy education — into one personalized, auto-adaptive daily therapy unit. The app is prescribed by physicians (PZN 20386496) and fully reimbursed by German statutory health insurers. A clinical study (MEMODIO_APP@CARE, n=140) demonstrated measurable improvements in cognitive function, daily living independence, physical activity, and quality of life after 12 weeks. memodio also provides a CME (continuing medical education) program for healthcare professionals.

Differentiator

Problem solved

Functional benefit

Products and services

  • memodio App Mobile digital therapeutic (iOS 12+ and Android 6+) prescribed by physicians in Germany as a Class I medical device (DiGA, PZN 20386496) for adults with mild cognitive impairment (ICD-10 F06.7) or mild dementia (F00/F01). Delivers a personalized, auto-adaptive daily therapy unit of approximately 20 minutes combining cognitive training, physical exercise, brain-healthy nutrition guidance, social participation content, risk factor optimization (e.g., hypertension, dyslipidemia, hearing loss), and health literacy modules. Fully reimbursed by German statutory and private health insurers upon prescription, with therapy delivered as 12-week prescription cycles (follow-up prescriptions possible).

Quantifiable outcome

  • 9.3% improvement in cognitive function (MoCA score) vs. control group after 12 weeks (p<0.001)
  • +6 more outcomes

Companies that use memodio

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

memodio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature8 records

memodio partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • SpinLab – The HPI AcceleratorminorStrategic or Co-development PartnerSpinLab, the HPI accelerator, is listed as a partner supporting memodio's development and growth.
  • Copenhagen Business School (CBS)minorStrategic or Co-development PartnerCopenhagen Business School (CBS) in Denmark is listed as a clinical and scientific partner supporting memodio's research.
  • Potsdam Transfer / University of PotsdamminorStrategic or Co-development PartnerPotsdam Transfer and the University of Potsdam support memodio as an academic and technology transfer partner, including hosting the company at their facilities (c/o Potsdam Transfer).
  • Medizinische Hochschule Theodor Fontane (MTH) PotsdamminorStrategic or Co-development PartnerMTH Potsdam is listed as a clinical and scientific partner supporting memodio's development.
  • FINGER Network (Karolinska Institutet)coreStrategic or Co-development PartnerThe FINGER Network (FINGERS Brain健康) coordinated by the Karolinska Institutet in Stockholm is a core strategic partner. memodio's therapeutic approach is based on the FINGER model — a landmark multi-domain intervention trial demonstrating that combined physical, cognitive, nutritional, and vascular risk management can prevent cognitive decline. Prof. Mangialasche (FINGER Vice-President) serves on memodio's Scientific Advisory Board.
  • memodio Scientific Advisory BoardcoreStrategic or Co-development PartnerThe Scientific Advisory Board includes Prof. M.C. Polidori (University Hospital Cologne), Prof. E. Kalbe (University Hospital Cologne), Prof. S. Schneider (German Sport University Cologne), Prof. M. Heer (Bonn University of Applied Sciences), Prof. G. Nelles (Deutsche Gesellschaft für Neurologie), Dr. A. Quante (Gedächtnisklinik Berlin), Prof. Mangialasche (FINGER Network, Karolinska), and Prof. P. Mecocci (Italian Academy of Geriatrics). The board provides clinical and scientific oversight to ensure the app meets the highest medical standards.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

memodio competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks3 records

Key highlights6 records

Customer concentration

memodio compliance and trust

Trust signal

Compliance3 records

memodio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

memodio leadership team

Management profile

Number of profiles

Profiles3 records

memodio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

memodio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about memodio

What does memodio do?

memodio develops and operates a DiGA (Digitale Gesundheitsanwendung — Digital Health Application) mobile app that delivers a personalized, multi-domain therapy program for adults with mild cognitive impairment (MCI) and mild dementia. The app combines adaptive cognitive training, guided physical exercise, brain-healthy nutrition guidance, social participation content, risk factor optimization, and health literacy into a single auto-adaptive daily therapy unit of approximately 20 minutes. It is prescribed by physicians in Germany on a Kassenrezept or private prescription and is fully reimbursed by statutory and private health insurers (PZN 20386496).

Is memodio a public or private company?

memodio is a private company. It is classified as venture growth investor backed and is currently operating.

When was memodio founded?

memodio was founded in 2021. It employs 11 to 50 people.

Where is memodio based?

memodio is headquartered in Potsdam, Germany, in the Europe region.

How does memodio make money?

Two revenue lines are on record. DiGA Prescription Reimbursement is the primary driver. The others are seed Funding.

Does memodio have an API?

No public API is recorded for memodio.

What industry is memodio in?

memodio's product category is Digital Therapeutics. Its primary akta.pro industry code is HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs), with a secondary code of HSABAEAH, Cognitive Stimulation & Reminiscence Therapy (Non-Clinical). Its NAICS code is 62161 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals